The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment

Official Title

Clinical Study Evaluating the Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment

Brief Summary

Efficacy of Ivermectin in larger doses in COVID-19 treatment

Detailed Description

Clinical Study Evaluating the Efficacy of Ivermectin in higher doses in COVID-19 treatment

Status

Recruiting

Conditions

COVID

Interventions

Drug: Ivermectin

ivermectin

Eligibility Criteria

Inclusion Criteria:

- Patients with covid 19

Exclusion Criteria:

- Allergy or side effects to treatment

Eligibility Gender

All

Eligibility Age

Minimum: N/A ~ Maximum: N/A

Countries

Egypt

Locations

Tanta University
Tanta, Egypt

Investigator: Sherief Abd-Elsalam

Contacts

Sherief Abd-Elsalam, ass. prof.
00201147773440
sheriefabdelsalam@yahoo.com

Investigators

sherief Abd-Elsalam, Ass. Prof., Principal Investigator
Tanta University - Faculty of Medicine

NCT Number

NCT04351347

MeSH Terms

Ivermectin

Disclaimer:

Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.

(202) 849 - 2075

1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036

navigator@reaganudall.org

Disclaimer:

Subscribe for updates from the Reagan-Udall Foundation for the FDA